OCR, the company revolutionising the selection of effective drug candidates for cancer, raises €1.25m from Newfund, NFA and the management team in order to accelerate its growth.
OCR is specialized in the conception
and management of clinical trials of pets
with naturally occurring pathologies for
efficacy assessment of drug candidates &
medical devices for Human and Animal Health.
For further information, please contact us.
+33 (0)3 20 56 82 93